Association of Weight Loss and Medication Adherence Among Adults With Type 2 Diabetes Mellitus: SHIELD (Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes)

Current Therapeutic Research - Clinical and Experimental

Volumn 75, Issue , 2013, Pages 77-82

  Grandy, Susan ^a   Fox, Kathleen M ^b   Hardy, Elise ^a   Bays, Harold ^c   Bazata, Debbra D ^d   Gavin, James R ^e   Green, Andrew J ^f   Lewis, Sandra J ^g   Reed, Michael L ^h   Rodbard, Helena W ^h,i  

^a ASTRAZENECA   (United Kingdom)

^b Strategic Healthcare Solutions LLC   (United States)

^c LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^d St Luke's Primary Care South   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Midwestern Endocrinology   (United States)

^g Northwest Cardiovascular Institute   (United States)

^h VEDANTA RESEARCH   (United States)

ⁱ Endocrine and Metabolic Associates   (United States)

Author keywords

Medication adherence; Sulfonylurea; Thiazolidinedione; Type 2 diabetes; Weight loss

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; METFORMIN; SULFONYLUREA;

ADULT; ARTICLE; ASSOCIATION; ATTITUDE TO HEALTH; CLINICAL EVALUATION; CONTROLLED STUDY; DEMOGRAPHY; DIET; DISEASE ASSOCIATION; EXERCISE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUESTIONNAIRE; RISK FACTOR; SCORING SYSTEM; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 84890137157     PISSN: 0011393X     EISSN: 18790313     Source Type: Journal    
DOI: 10.1016/j.curtheres.2013.06.004     Document Type: Article

References (36)

1. American Diabetes Association. Diabetes Statistics. Accessed April 3, 2012. http://www.diabetes.org/diabetes-basics/diabetes-statistics.
2. International Diabetes Federation. Diabetes Atlas. Accessed April 3, 2012. http://www.diabetesatlas.org.
3. Wild H. The economic rationale for adherence in the treatment of type 2 diabetes mellitus. Am J Manag Care 2012, 18:S43-S48.
4. Tiv M., Viel J.-F., Mauny F., et al. Medication adherence in type 2 diabetes: the ENTRED study 2007, a French population-based study. PLoS One 2012, 7:e32412.
5. Cramer J.A. A systematic review of adherence with medications for diabetes. Diabetes Care 2004, 27:1218-1224.
6. Sokol M.C., McGuigan K.A., Verbrugge R.R., Epstein R.S. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005, 43:521-530.
7. Lee W.C., Balu S., Cobden D., et al. Prevalence and economic consequences of medication adherence in diabetes: a systematic literature review. Manag Care Interface 2006, 19:31-41.
8. Nagrebetsky A., Griffin S., Kinmonth A.L., et al. Predictors of suboptimal glycaemic control in type 2 diabetes patients: the role of medication adherence and body mass index in the relationship between glycaemia and age. Diabetes Res Clin Pract 2012, 96:119-128.
9. Rhee M.K., Slocum W., Ziemer D.C., et al. Patient adherence improves glycemic control. Diabetes Educ 2005, 31:240-250.
10. Krapek K., King K., Warren S.S., et al. Medication adherence and associated hemoglobin A1c in type 2 diabetes. Ann Pharmacother 2004, 38:1357-1362.
11. Stuart B.C., Simoni-Wastila L., Zhao L., et al. Increased persistency in medication use by U.S. Medicare beneficiaries with diabetes is associated with lower hospitalization rates and cost savings. Diabetes Care 2009, 32:647-649.
12. Salas M., Hughes D., Zuluaga A., et al. Costs of medication nonadherence in patients with diabetes mellitus: a systemic review and critical analysis of the literature. Value Health 2009, 12:915-922.
13. Jha A.K., Aubert R.E., Yao J., et al. Greater adherence to diabetes drugs is linked to less hospital use and could save nearly $5 billion annually. Health Aff (Millwood) 2012, 31:1836-1846.
14. Carls G.S., Roebuck M.C., Brennan T.A., et al. Impact of medication adherence on absenteeism and short-term disability for five chronic diseases. J Occup Environ Med 2012, 54:792-805.
15. Daousi C., Casson I.F., Gill G.V., et al. Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors. Postgrad Med J 2006, 82:280-284.
16. Ross S.A., Dzida G., Vora J., et al. Impact of weight gain on outcomes in type 2 diabetes. Curr Med Res Opin 2011, 27:1431-1438.
17. Pani L.N., Nathan D.M., Grant R.W. Clinical predictors of disease progression and medication initiation in untreated patients with type 2 diabetes and A1C less than 7%. Diabetes Care 2008, 31:386-390.
18. Wannamethee S.G., Shaper A.G., Walker M. Overweight and obesity and weight change in middle aged men: impact on cardiovascular disease and diabetes. J Epidemiol Community Health 2005, 59:134-139.
19. Anderson J.W., Kendall C.W.C., Jenkins D.J.A. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr 2003, 22:331-339.
20. Feldstein A.C., Nichols G.A., Smith D.H., et al. Weight change in diabetes and glycemic and blood pressure control. Diabetes Care 2008, 31:1960-1965.
21. DeFronzo R.A. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. Diabetologia 2010, 53:1270-1287.
22. Yu A.P., Wu E.Q., Birnbaum H.G., et al. Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data. Curr Med Res Opin 2007, 23:2157-2169.
23. Chaudhuri A., Rosenstock J., DiGenio A., et al. Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis. Diabetes Metab Res Rev 2012, 28:258-267.
24. Boldo A., Comi R.J. Clinical experience with U500 insulin: risks and benefits. Endocr Pract 2012, 18:56-61.
25. Morgan C.L., Jenkins-Jones S., Evans M., et al. Weight change in people with type 2 diabetes: secular trends and the impact of alternative antihyperglycaemic drugs. Diabetes Obes Metab 2012, 14:424-432.
26. Phung O.J., Scholle J.M., Talwar M., Coleman C.I. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 2010, 303:1410-1418.
27. Pinelli N.R., Hurren K.M. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis. Ann Pharmacother 2011, 45:850-860.
28. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care 2012, 35:731-737. Diabetes Prevention Program Research Group.
29. Bays H.E., Chapman R.H., Grandy S. The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys. Int J Clin Pract 2007, 61:737-747. for the SHIELD Investigators Group.
30. Bays H.E., Bazata D.D., Clark N.G., et al. Prevalence of self-reported diagnosis of diabetes mellitus and associated risk factors in a national survey in the US population: SHIELD (Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes). BMC Public Health 2007, 7:277.
31. Annual Supplement to the Current Population Survey: Census Bureau Resident Population Estimates of the United States 2003, US Census Bureau, Census Bureau, Washington, DC: U.S.
32. Kaukua J.K., Pekkarinen T.A., Rissanen A.M. Health-related quality of life in a randomized placebo-controlled trial of sibutramine in obese patients with type II diabetes. Int J Obes Relat Metab Disord 2004, 28:600-605.
33. Morisky D.E., Green L.W., Levine D.M. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986, 24:67-74.
34. Natarajan N., Putnam R.W., Yip A.M., Frail D. Family practice patients' adherence to statin medications. Can Fam Physician 2007, 53:2144-2145.
35. Shalansky S.J., Levy A.R., Ignaszewski A.P. Self-reported Morisky score for identifying nonadherence with cardiovascular medications. Ann Pharmacother 2004, 38:1363-1368.
36. Craig C.L., Marshall A.L., Sjostrom M., et al. International Physical Activity Questionnaire (IPAQ): 12-country reliability and validity. Med Sci Sports Exerc 2003, 35:1381-1395.